CRN on ODS
This article was originally published in The Tan Sheet
NIH's Office of Dietary Supplements "should overtly and in a transparent manner offer its reports as advice," CRN VP-Scientific & International Affairs John Hathcock, PhD, said in materials presented during a meeting on ODS' five-year Strategic Plan May 20 in Bethesda, Md. Hathcock noted that some needs are not being met to expand outreach to the public, scientists and healthcare providers. The CRN VP also recommended that the HHS secretary and agency heads at CDC and NIH "should overtly seek and consider the advice of ODS on [dietary supplement] issues"...
You may also be interested in...
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.